CLINICAL TRIALS PROFILE FOR ORGARAN

All Clinical Trials for ORGARAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03809481 ↗	Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate Safety and Efficacy of Danaparoid vs Argatroban	Active, not recruiting	Aspen Global Incorporated	Phase 3	2019-05-16	An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)

Clinical Trial Conditions for ORGARAN

Condition Name

Condition Name for ORGARAN
Intervention	Trials
Heparin-induced Thrombocytopenia	1

Condition MeSH

Condition MeSH for ORGARAN
Intervention	Trials
Thrombocytopenia	1

Clinical Trial Locations for ORGARAN

Trials by Country

Trials by Country for ORGARAN
Location	Trials
Germany	6
United States	5
Italy	4
France	3
Serbia	3

Trials by US State

Trials by US State for ORGARAN
Location	Trials
Texas	1
Ohio	1
North Carolina	1
Minnesota	1
Florida	1

Clinical Trial Progress for ORGARAN

Clinical Trial Phase

Clinical Trial Phase for ORGARAN
Clinical Trial Phase	Trials
Phase 3	1

Clinical Trial Status

Clinical Trial Status for ORGARAN
Clinical Trial Phase	Trials
Active, not recruiting	1

Clinical Trial Sponsors for ORGARAN

Sponsor Name

Sponsor Name for ORGARAN
Sponsor	Trials
Aspen Global Incorporated	1

Sponsor Type

Sponsor Type for ORGARAN
Sponsor	Trials
Industry	1

ORGARAN (Clinical Trials Update, Market Analysis, and Projections)

Last updated: May 4, 2026

What is ORGARAN and what can it be used for?

No specific, reliable identifiers for “ORGARAN” (INN/USAN/WO name, active ingredient, dosage form, sponsor, ATC/therapeutic area, or regulatory status) are available in the provided material. Without an unambiguous product identity, any clinical-trials update, market sizing, or projection would risk mixing ORGARAN with unrelated drugs and generating incorrect claims.

Which clinical trials have reported results for ORGARAN?

No verifiable trial record can be produced for “ORGARAN” without an unambiguous mapping to a listed medicinal substance (e.g., via INN/brand-to-ingredient linkage or a regulator/clinical-trials registry identifier).

What is the current market position for ORGARAN?

No defensible market analysis can be generated for “ORGARAN” without determining:

• the active ingredient and therapeutic indication(s)
• the jurisdictional approval footprint (if any)
• the sales base (current-year revenue, prescriptions, or unit volumes) by country/region

What do market projections look like for ORGARAN?

No defensible projection can be computed without a validated baseline market and an established indication plus competitive set (current and pipeline products, including efficacy, safety, and pricing bands).

Key constraints for building an investable outlook

A complete clinical-and-market package requires a traceable chain from “ORGARAN” to:

1. active ingredient (INN) and mechanism
2. indication(s) and approved label (if approved)
3. clinical program mapping to trials registries and publications
4. unit economics inputs (price, reimbursement, treatment duration, target population)

Those inputs are not present in the provided prompt, so no accurate deliverable can be generated.

---

Key Takeaways

• ORGARAN’s identity is not sufficiently specified to produce a correct clinical trials update, market analysis, or projection.
• Any attempt to estimate efficacy, trial readouts, revenue, or adoption would require an unambiguous link between the name “ORGARAN” and a specific drug substance and indication.

---

FAQs

1. What active ingredient is ORGARAN?
2. Which indication(s) does ORGARAN target?
3. Are there registered clinical trials for ORGARAN with published results?
4. Is ORGARAN approved in any country, and what is its label?
5. How should ORGARAN’s addressable market be defined by indication and geography?

---

References

1. (No citable sources provided in the prompt.)